| Data . | CMIII . | Cryo LA . | HIFU . | Other . | Total result . | P-value . |
|---|---|---|---|---|---|---|
| n | 29 | 22 | 46 | 2 | 99 | |
| Follow-up | 1.13 ± 0.82 (0.09, 3.63) | 1.44 ± 1.05 (0.11–4.6) | 1.41 ± 0.95 (0.13–4.07) | 0.53 ± 0.2 (0.28–0.76) | 1.34 ± 0.95 (0.09–4.6) | 0.02 |
| NYHA | ||||||
| Class I | 16 | 10 | 15 | 0 | 41 | 0.14 |
| Class II | 3 | 7 | 15 | 1 | 26 | |
| Class III | 2 | 1 | 5 | 0 | 8 | |
| Class IV | 0 | 0 | 0 | 0 | 0 | |
| Unknown | 8 | 4 | 11 | 1 | 24 | |
| EHRA | ||||||
| EHRA I | 17 | 17 | 29 | 1 | 64 | 0.62 |
| EHRA II | 2 | 0 | 2 | 0 | 4 | |
| EHRA III | 1 | 0 | 1 | 0 | 2 | |
| EHRA IV | 0 | 0 | 0 | 0 | 0 | |
| Unknown | 9 | 5 | 14 | 1 | 29 | |
| AF burden | ||||||
| Mean ± SD | 0.089 ± 0.243 | 0.004 ± 0.009 | 0.087 ± 0.197 | 0.001 ± 0.001 | 0.067 ± 0.190 | 0.025 |
| 1st quartile–median–3rd quartile | 0.001–0.001–0.004 | 0.001–0.001–0.002 | 0.001–0.004–0.048 | 0.001–0.002–0.002 | 0.001–0.002–0.019 | |
| Patients with AF burden <0.01 | 23 (79.3%) | 19 (86.4%) | 27 (58.7%) | 2 (100%) | 71 (71.7%) | |
| Patients with AF burden <0.05 | 24 (82.8%) | 22 (100%) | 34 (73.9%) | 2 (100%) | 82 (82.8%) | |
| LVEF | 56.1 ± 11.2 (28–83) | 57.63 ± 9.78 (40–75) | 55.88 ± 11.19 (18–81) | 70.33 ± 12.1 (61–84) | 56.47 ± 10.96 (18–84) | 0.70 |
| LAD parasternal | 4.81 ± 0.68 (2.77–6.5) | 5.57 ± 5.5 (3.1–53) | 5.31 ± 5.13 (2.9–48) | 4.4 ± 0.9 (3.5–5.3) | 5.21 ± 4.34 (2.77–53) | 0.28 |
| MR | ||||||
| None/trivial | 11 | 13 | 10 | 1 | 35 | 0.24 |
| Grade I | 8 | 5 | 14 | 0 | 27 | |
| Grade II | 0 | 0 | 1 | 0 | 1 | |
| Unknown | 10 | 4 | 21 | 1 | 36 | |
| Cardioversion attempt | ||||||
| Electrical (n; time range in years) | 8 (0.02–2.9) | 1 (0.1) | 19 (0.16–3.3) | 0 | 28 (0.016–3.3) | 0.002 |
| Pharmacological (n; time range in years) | 1 (2.9) | 0 | 6 (0.7–3.9) | 0 | 7 (0.7–3.9) | 0.88 |
| Complications (n of events) | ||||||
| Major bleeding events | 1 | 1 | ||||
| Re-ablation | 0 | 2 | 3 | 5 | ||
| TIA | 0 | 0 | 0 | 0 | 0 | |
| PRIND | 0 | 0 | 0 | 0 | 0 | |
| Stroke | 1 | 0 | 1 | 0 | 2 | |
| Medication | ||||||
| Sotalol | 0 | 0 | 1 | 0 | 1 | |
| β-Blocker | 24 | 20 | 28 | 1 | 73 | |
| Amiodarone | 13 | 9 | 17 | 1 | 40 | |
| Digitalis | 5 | 5 | 4 | 0 | 14 | |
| Dronedarone | 1 | 1 | 1 | 0 | 3 | |
| Warfarin | 27 | 19 | 27 | 0 | 73 | |
| Aspirin | 7 | 7 | 13 | 1 | 28 | |
| Data . | CMIII . | Cryo LA . | HIFU . | Other . | Total result . | P-value . |
|---|---|---|---|---|---|---|
| n | 29 | 22 | 46 | 2 | 99 | |
| Follow-up | 1.13 ± 0.82 (0.09, 3.63) | 1.44 ± 1.05 (0.11–4.6) | 1.41 ± 0.95 (0.13–4.07) | 0.53 ± 0.2 (0.28–0.76) | 1.34 ± 0.95 (0.09–4.6) | 0.02 |
| NYHA | ||||||
| Class I | 16 | 10 | 15 | 0 | 41 | 0.14 |
| Class II | 3 | 7 | 15 | 1 | 26 | |
| Class III | 2 | 1 | 5 | 0 | 8 | |
| Class IV | 0 | 0 | 0 | 0 | 0 | |
| Unknown | 8 | 4 | 11 | 1 | 24 | |
| EHRA | ||||||
| EHRA I | 17 | 17 | 29 | 1 | 64 | 0.62 |
| EHRA II | 2 | 0 | 2 | 0 | 4 | |
| EHRA III | 1 | 0 | 1 | 0 | 2 | |
| EHRA IV | 0 | 0 | 0 | 0 | 0 | |
| Unknown | 9 | 5 | 14 | 1 | 29 | |
| AF burden | ||||||
| Mean ± SD | 0.089 ± 0.243 | 0.004 ± 0.009 | 0.087 ± 0.197 | 0.001 ± 0.001 | 0.067 ± 0.190 | 0.025 |
| 1st quartile–median–3rd quartile | 0.001–0.001–0.004 | 0.001–0.001–0.002 | 0.001–0.004–0.048 | 0.001–0.002–0.002 | 0.001–0.002–0.019 | |
| Patients with AF burden <0.01 | 23 (79.3%) | 19 (86.4%) | 27 (58.7%) | 2 (100%) | 71 (71.7%) | |
| Patients with AF burden <0.05 | 24 (82.8%) | 22 (100%) | 34 (73.9%) | 2 (100%) | 82 (82.8%) | |
| LVEF | 56.1 ± 11.2 (28–83) | 57.63 ± 9.78 (40–75) | 55.88 ± 11.19 (18–81) | 70.33 ± 12.1 (61–84) | 56.47 ± 10.96 (18–84) | 0.70 |
| LAD parasternal | 4.81 ± 0.68 (2.77–6.5) | 5.57 ± 5.5 (3.1–53) | 5.31 ± 5.13 (2.9–48) | 4.4 ± 0.9 (3.5–5.3) | 5.21 ± 4.34 (2.77–53) | 0.28 |
| MR | ||||||
| None/trivial | 11 | 13 | 10 | 1 | 35 | 0.24 |
| Grade I | 8 | 5 | 14 | 0 | 27 | |
| Grade II | 0 | 0 | 1 | 0 | 1 | |
| Unknown | 10 | 4 | 21 | 1 | 36 | |
| Cardioversion attempt | ||||||
| Electrical (n; time range in years) | 8 (0.02–2.9) | 1 (0.1) | 19 (0.16–3.3) | 0 | 28 (0.016–3.3) | 0.002 |
| Pharmacological (n; time range in years) | 1 (2.9) | 0 | 6 (0.7–3.9) | 0 | 7 (0.7–3.9) | 0.88 |
| Complications (n of events) | ||||||
| Major bleeding events | 1 | 1 | ||||
| Re-ablation | 0 | 2 | 3 | 5 | ||
| TIA | 0 | 0 | 0 | 0 | 0 | |
| PRIND | 0 | 0 | 0 | 0 | 0 | |
| Stroke | 1 | 0 | 1 | 0 | 2 | |
| Medication | ||||||
| Sotalol | 0 | 0 | 1 | 0 | 1 | |
| β-Blocker | 24 | 20 | 28 | 1 | 73 | |
| Amiodarone | 13 | 9 | 17 | 1 | 40 | |
| Digitalis | 5 | 5 | 4 | 0 | 14 | |
| Dronedarone | 1 | 1 | 1 | 0 | 3 | |
| Warfarin | 27 | 19 | 27 | 0 | 73 | |
| Aspirin | 7 | 7 | 13 | 1 | 28 | |
EHRA and NYHA represent values at latest follow up.
TIA: transient ischaemic attack; PRIND: prolonged reversible ischaemic neurological deficit; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; LAD: left atrial diameter; EHRA: European Heart Rhythm Association class; CMIII: Cox Maze III; Cryo LA: left atrial cryoablation; HIFU: high-intensity focused ultrasound; SD: standard deviation.
| Data . | CMIII . | Cryo LA . | HIFU . | Other . | Total result . | P-value . |
|---|---|---|---|---|---|---|
| n | 29 | 22 | 46 | 2 | 99 | |
| Follow-up | 1.13 ± 0.82 (0.09, 3.63) | 1.44 ± 1.05 (0.11–4.6) | 1.41 ± 0.95 (0.13–4.07) | 0.53 ± 0.2 (0.28–0.76) | 1.34 ± 0.95 (0.09–4.6) | 0.02 |
| NYHA | ||||||
| Class I | 16 | 10 | 15 | 0 | 41 | 0.14 |
| Class II | 3 | 7 | 15 | 1 | 26 | |
| Class III | 2 | 1 | 5 | 0 | 8 | |
| Class IV | 0 | 0 | 0 | 0 | 0 | |
| Unknown | 8 | 4 | 11 | 1 | 24 | |
| EHRA | ||||||
| EHRA I | 17 | 17 | 29 | 1 | 64 | 0.62 |
| EHRA II | 2 | 0 | 2 | 0 | 4 | |
| EHRA III | 1 | 0 | 1 | 0 | 2 | |
| EHRA IV | 0 | 0 | 0 | 0 | 0 | |
| Unknown | 9 | 5 | 14 | 1 | 29 | |
| AF burden | ||||||
| Mean ± SD | 0.089 ± 0.243 | 0.004 ± 0.009 | 0.087 ± 0.197 | 0.001 ± 0.001 | 0.067 ± 0.190 | 0.025 |
| 1st quartile–median–3rd quartile | 0.001–0.001–0.004 | 0.001–0.001–0.002 | 0.001–0.004–0.048 | 0.001–0.002–0.002 | 0.001–0.002–0.019 | |
| Patients with AF burden <0.01 | 23 (79.3%) | 19 (86.4%) | 27 (58.7%) | 2 (100%) | 71 (71.7%) | |
| Patients with AF burden <0.05 | 24 (82.8%) | 22 (100%) | 34 (73.9%) | 2 (100%) | 82 (82.8%) | |
| LVEF | 56.1 ± 11.2 (28–83) | 57.63 ± 9.78 (40–75) | 55.88 ± 11.19 (18–81) | 70.33 ± 12.1 (61–84) | 56.47 ± 10.96 (18–84) | 0.70 |
| LAD parasternal | 4.81 ± 0.68 (2.77–6.5) | 5.57 ± 5.5 (3.1–53) | 5.31 ± 5.13 (2.9–48) | 4.4 ± 0.9 (3.5–5.3) | 5.21 ± 4.34 (2.77–53) | 0.28 |
| MR | ||||||
| None/trivial | 11 | 13 | 10 | 1 | 35 | 0.24 |
| Grade I | 8 | 5 | 14 | 0 | 27 | |
| Grade II | 0 | 0 | 1 | 0 | 1 | |
| Unknown | 10 | 4 | 21 | 1 | 36 | |
| Cardioversion attempt | ||||||
| Electrical (n; time range in years) | 8 (0.02–2.9) | 1 (0.1) | 19 (0.16–3.3) | 0 | 28 (0.016–3.3) | 0.002 |
| Pharmacological (n; time range in years) | 1 (2.9) | 0 | 6 (0.7–3.9) | 0 | 7 (0.7–3.9) | 0.88 |
| Complications (n of events) | ||||||
| Major bleeding events | 1 | 1 | ||||
| Re-ablation | 0 | 2 | 3 | 5 | ||
| TIA | 0 | 0 | 0 | 0 | 0 | |
| PRIND | 0 | 0 | 0 | 0 | 0 | |
| Stroke | 1 | 0 | 1 | 0 | 2 | |
| Medication | ||||||
| Sotalol | 0 | 0 | 1 | 0 | 1 | |
| β-Blocker | 24 | 20 | 28 | 1 | 73 | |
| Amiodarone | 13 | 9 | 17 | 1 | 40 | |
| Digitalis | 5 | 5 | 4 | 0 | 14 | |
| Dronedarone | 1 | 1 | 1 | 0 | 3 | |
| Warfarin | 27 | 19 | 27 | 0 | 73 | |
| Aspirin | 7 | 7 | 13 | 1 | 28 | |
| Data . | CMIII . | Cryo LA . | HIFU . | Other . | Total result . | P-value . |
|---|---|---|---|---|---|---|
| n | 29 | 22 | 46 | 2 | 99 | |
| Follow-up | 1.13 ± 0.82 (0.09, 3.63) | 1.44 ± 1.05 (0.11–4.6) | 1.41 ± 0.95 (0.13–4.07) | 0.53 ± 0.2 (0.28–0.76) | 1.34 ± 0.95 (0.09–4.6) | 0.02 |
| NYHA | ||||||
| Class I | 16 | 10 | 15 | 0 | 41 | 0.14 |
| Class II | 3 | 7 | 15 | 1 | 26 | |
| Class III | 2 | 1 | 5 | 0 | 8 | |
| Class IV | 0 | 0 | 0 | 0 | 0 | |
| Unknown | 8 | 4 | 11 | 1 | 24 | |
| EHRA | ||||||
| EHRA I | 17 | 17 | 29 | 1 | 64 | 0.62 |
| EHRA II | 2 | 0 | 2 | 0 | 4 | |
| EHRA III | 1 | 0 | 1 | 0 | 2 | |
| EHRA IV | 0 | 0 | 0 | 0 | 0 | |
| Unknown | 9 | 5 | 14 | 1 | 29 | |
| AF burden | ||||||
| Mean ± SD | 0.089 ± 0.243 | 0.004 ± 0.009 | 0.087 ± 0.197 | 0.001 ± 0.001 | 0.067 ± 0.190 | 0.025 |
| 1st quartile–median–3rd quartile | 0.001–0.001–0.004 | 0.001–0.001–0.002 | 0.001–0.004–0.048 | 0.001–0.002–0.002 | 0.001–0.002–0.019 | |
| Patients with AF burden <0.01 | 23 (79.3%) | 19 (86.4%) | 27 (58.7%) | 2 (100%) | 71 (71.7%) | |
| Patients with AF burden <0.05 | 24 (82.8%) | 22 (100%) | 34 (73.9%) | 2 (100%) | 82 (82.8%) | |
| LVEF | 56.1 ± 11.2 (28–83) | 57.63 ± 9.78 (40–75) | 55.88 ± 11.19 (18–81) | 70.33 ± 12.1 (61–84) | 56.47 ± 10.96 (18–84) | 0.70 |
| LAD parasternal | 4.81 ± 0.68 (2.77–6.5) | 5.57 ± 5.5 (3.1–53) | 5.31 ± 5.13 (2.9–48) | 4.4 ± 0.9 (3.5–5.3) | 5.21 ± 4.34 (2.77–53) | 0.28 |
| MR | ||||||
| None/trivial | 11 | 13 | 10 | 1 | 35 | 0.24 |
| Grade I | 8 | 5 | 14 | 0 | 27 | |
| Grade II | 0 | 0 | 1 | 0 | 1 | |
| Unknown | 10 | 4 | 21 | 1 | 36 | |
| Cardioversion attempt | ||||||
| Electrical (n; time range in years) | 8 (0.02–2.9) | 1 (0.1) | 19 (0.16–3.3) | 0 | 28 (0.016–3.3) | 0.002 |
| Pharmacological (n; time range in years) | 1 (2.9) | 0 | 6 (0.7–3.9) | 0 | 7 (0.7–3.9) | 0.88 |
| Complications (n of events) | ||||||
| Major bleeding events | 1 | 1 | ||||
| Re-ablation | 0 | 2 | 3 | 5 | ||
| TIA | 0 | 0 | 0 | 0 | 0 | |
| PRIND | 0 | 0 | 0 | 0 | 0 | |
| Stroke | 1 | 0 | 1 | 0 | 2 | |
| Medication | ||||||
| Sotalol | 0 | 0 | 1 | 0 | 1 | |
| β-Blocker | 24 | 20 | 28 | 1 | 73 | |
| Amiodarone | 13 | 9 | 17 | 1 | 40 | |
| Digitalis | 5 | 5 | 4 | 0 | 14 | |
| Dronedarone | 1 | 1 | 1 | 0 | 3 | |
| Warfarin | 27 | 19 | 27 | 0 | 73 | |
| Aspirin | 7 | 7 | 13 | 1 | 28 | |
EHRA and NYHA represent values at latest follow up.
TIA: transient ischaemic attack; PRIND: prolonged reversible ischaemic neurological deficit; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; LAD: left atrial diameter; EHRA: European Heart Rhythm Association class; CMIII: Cox Maze III; Cryo LA: left atrial cryoablation; HIFU: high-intensity focused ultrasound; SD: standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
